Page 2092 - Hematology_ Basic Principles and Practice ( PDFDrive )

Chapter 123 The Blood Vessel Wall 1856.e5

218. Marcus AJ, Broekman MJ, Drosopoulos JH, et al: Role of CD39 251. von Andrian UH, Berger EM, Ramezani L, et al: In vivo behavior of
(NTPDase-1) in thromboregulation, cerebroprotection, and cardio- neutrophils from two patients with distinct inherited leukocyte adhe-
protection. Semin Thromb Hemost 31:234, 2005. sion deficiency syndromes. J Clin Invest 91:2893, 1993.
219. Zimmermann H: Nucleotides and CD39: principal modulatory players 252. Mizgerd JP, Meek BB, Kutkoski GJ, et al: Selectins and neutrophil
in hemostasis and thrombosis. Nat Med 5:987, 1999. traffic: margination and Streptococcus pneumoniae-induced emigra-
220. Levi M, ten Cate H, van der Poll T: Endothelium: Interface between tion in murine lungs. J Exp Med 184:639, 1996.
coagulation and inflammation. Crit Care Med 30:S220, 2002. 253. Wong J, Johnston B, Lee SS, et al: A minimal role for selectins in the
221. Arnout J, Hoylaerts MF, Lijnen HR: Haemostasis. Handb Exp Phar- recruitment of leukocytes into the inflamed liver microvasculature. J
macol 176:1, 2006. Clin Invest 99:2782, 1997.
222. Dahlback B, Villoutreix BO: The anticoagulant protein C pathway. 254. DeGrendele HC, Estess P, Picker LJ, et al: CD44 and its ligand hya-
FEBS Lett 579:3310, 2005. luronate mediate rolling under physiologic flow: a novel lymphocyte-
223. Lwaleed BA, Bass PS: Tissue factor pathway inhibitor: structure, biology endothelial cell primary adhesion pathway. J Exp Med 183:1119,
and involvement in disease. J Pathol 208:327, 2006. 1996.
224. Wu KK, Thiagarajan P: Role of endothelium in thrombosis and 255. Salmi M, Yegutkin GG, Lehvonen R, et al: A cell surface amine
hemostasis. Annu Rev Med 47:315, 1996. oxidase directly controls lymphocyte migration. Immunity 14:265,
225. Lijnen HR, Collen D: Endothelium in hemostasis and thrombosis. Prog 2001.
Cardiovasc Dis 39:343, 1997. 256. Weber C: Novel mechanistic concepts for the control of leukocyte
226. Flynn PD, Byrne CD, Baglin TP, et al: Thrombin generation by transmigration: specialization of integrins, chemokines, and junctional
apoptotic vascular smooth muscle cells. Blood 89:4378, 1997. molecules. J Mol Med 81:4, 2003.
227. Winn RK, Harlan JM: The role of endothelial cell apoptosis in inflam- 257. Petri B, Bixel MG: Molecular events during leukocyte diapedesis. FEBS
matory and immune diseases. J Thromb Haemost 3:2005, 1815. J 273:4399, 2006.
228. Osterud B, Bjorklid E: Sources of tissue factor. Semin Thromb Hemost 258. Millan J, Hewlett L, Glyn M, et al: Lymphocyte transcellular migration
32:11, 2006. occurs through recruitment of endothelial ICAM-1 to caveola- and
229. Morel O, Toti F, Hugel B, et al: Procoagulant microparticles: disrupt- F-actin-rich domains. Nat Cell Biol 8:113, 2006.
ing the vascular homeostasis equation? Arterioscler Thromb Vasc Biol 259. Muller WA, Weigl SA, Deng X, et al: PECAM-1 is required for tran-
26:2594, 2006. sendothelial migration of leukocytes. J Exp Med 178:449, 1993.
230. Piccin A, Murphy WG, Smith OP: Circulating microparticles: patho- 260. Ostermann G, Weber KS, Zernecke A, et al: JAM-1 is a ligand of
physiology and clinical implications. Blood Rev 21:157, 2006. the beta(2) integrin LFA-1 involved in transendothelial migration of
231. Busse R, Fleming I: Endothelial dysfunction in atherosclerosis. J Vasc leukocytes. Nat Immunol 3:151, 2002.
Res 33:181, 1996. 261. Schenkel AR, Mamdouh Z, Chen X, et al: CD99 plays a major role
232. Vane JR, Anggard EE, Botting RM: Regulatory functions of the in the migration of monocytes through endothelial junctions. Nat
vascular endothelium. N Engl J Med 323:27, 1990. Immunol 3:143, 2002.
233. Bassenge E: Endothelial function in different organs. Prog Cardiovasc 262. Seelige R, Natsch C, Marz S, et al: Cutting edge: Endothelial-specific
Dis 39:209, 1996. gene ablation of CD99L2 impairs leukocyte extravasation in vivo. J
234. Upchurch GR, Jr, Welch GN, Loscalzo J: Homocysteine, EDRF, and Immunol 190:892, 2013.
endothelial function. J Nutr 126:1290S, 1996. 263. Wegmann F, Petri B, Khandoga AG, et al: ESAM supports neutrophil
235. Motterlini R, Vandegriff KD, Winslow RM: Hemoglobin-nitric oxide extravasation, activation of Rho, and VEGF-induced vascular perme-
interaction and its implications. Transfus Med Rev 10:77, 1996. ability. J Exp Med 203:1671, 2006.
236. Stamler JS, Jia L, Eu JP, et al: Blood flow regulation by 264. Reymond N, Imbert AM, Devilard E, et al: DNAM-1 and PVR
S-nitrosohemoglobin in the physiological oxygen gradient. Science regulate monocyte migration through endothelial junctions. J Exp Med
276:2034, 1997. 199:1331, 2004.
237. De Meyer GR, Herman AG: Vascular endothelial dysfunction. Prog 265. Azcutia V, Stefanidakis M, Tsuboi N, et al: Endothelial CD47 promotes
Cardiovasc Dis 39:325, 1997. vascular endothelial-cadherin tyrosine phosphorylation and participates
238. Feletou M, Vanhoutte PM: Endothelium-derived hyperpolarizing in T cell recruitment at sites of inflammation in vivo. J Immunol
factor: where are we now? Arterioscler Thromb Vasc Biol 26:1215, 2006. 189:2553, 2012.
239. Masaki T: Possible role of endothelin in endothelial regulation of 266. Hordijk PL: Endothelial signalling events during leukocyte transmigra-
vascular tone. Annu Rev Pharmacol Toxicol 35:235, 1995. tion. FEBS J 273:4408, 2006.
240. Levin ER: Endothelins. N Engl J Med 333:356, 1995. 267. Feng D, Nagy JA, Pyne K, et al: Neutrophils emigrate from venules by a
241. Galie N, Manes A, Branzi A: Emerging medical therapies for pulmonary transendothelial cell pathway in response to FMLP. J Exp Med 187:903,
arterial hypertension. Prog Cardiovasc Dis 45:213, 2002. 1998.
242. Vatter H, Seifert V: Ambrisentan, a non-peptide endothelin receptor 268. Subramaniam M, Koedam JA, Wagner DD: Divergent fates of P- and
antagonist. Cardiovasc Drug Rev 24:63, 2006. E-selectins after their expression on the plasma membrane. Mol Biol
243. Katusic ZS: Superoxide anion and endothelial regulation of arterial Cell 4:791, 1993.
tone. Free Radic Biol Med 20:443, 1996. 269. Kishimoto TK, Jutila MA, Berg EL, et al: Neutrophil Mac-1 and
244. Rosendorff C: Endothelin, vascular hypertrophy, and hypertension. MEL-14 adhesion proteins inversely regulated by chemotactic factors.
Cardiovasc Drugs Ther 10:795, 1997. Science 245:1238, 1989.
245. Luster AD, Alon R, von Andrian UH: Immune cell migration in 270. Kubes P, Suzuki M, Granger DN: Nitric oxide: an endogenous modula-
inflammation: present and future therapeutic targets. Nat Immunol tor of leukocyte adhesion. Proc Natl Acad Sci USA 88:4651, 1991.
6:1182, 2005. 271. Smith WB, Noack L, Khew Goodall Y, et al: Transforming growth
246. Ley K, Reutershan J: Leucocyte-endothelial interactions in health and factor-beta 1 inhibits the production of IL-8 and the transmigration
disease. Handb Exp Pharmacol 176:97, 2006. of neutrophils through activated endothelium. J Immunol 157:360,
247. McEver RP: Selectins: lectins that initiate cell adhesion under flow. Curr 1996.
Opin Cell Biol 14:581, 2002. 272. Sata M, Walsh K: TNFalpha regulation of Fas ligand expression on
248. Kinashi T: Intracellular signalling controlling integrin activation in the vascular endothelium modulates leukocyte extravasation. Nat Med
lymphocytes. Nat Rev Immunol 5:546, 2005. 4:415, 1998.
249. Kuijpers TW, Mul EP, Blom M, et al: Freezing adhesion molecules in 273. Cornejo CJ, Winn RK, Harlan JM: Anti-adhesion therapy. Adv Phar-
a state of high-avidity binding blocks eosinophil migration. J Exp Med macol 39:99, 1997.
178:279, 1993. 274. Ulbrich H, Eriksson EE, Lindbom L: Leukocyte and endothelial cell
250. Kubes P: The complexities of leukocyte recruitment. Semin Immunol adhesion molecules as targets for therapeutic interventions in inflam-
14:65, 2002. matory disease. Trends Pharmacol Sci 24:640, 2003.